The patient’s tumor was sequenced with the MSK-IMPACT assay21 as part of his clinical evaluation, as above, inferring a fusion between FGFR2 and G3BP2. The MSK-IMPACT assay was subsequently used to analyze DUC18828. This evidence concerns the gene G3BP2 and neoplasm.